These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 12722161)

  • 1. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.
    Smith LA; Jackson MJ; Hansard MJ; Maratos E; Jenner P
    Mov Disord; 2003 May; 18(5):487-95. PubMed ID: 12722161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.
    Smith LA; Jackson MJ; Al-Barghouthy G; Rose S; Kuoppamaki M; Olanow W; Jenner P
    Mov Disord; 2005 Mar; 20(3):306-14. PubMed ID: 15490461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates.
    Zubair M; Jackson MJ; Tayarani-Binazir K; Stockwell KA; Smith LA; Rose S; Olanow W; Jenner P
    Exp Neurol; 2007 Dec; 208(2):177-84. PubMed ID: 17935716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets.
    Smith LA; Gordin A; Jenner P; Marsden CD
    Mov Disord; 1997 Nov; 12(6):935-45. PubMed ID: 9399218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
    Hansard MJ; Smith LA; Jackson MJ; Cheetham SC; Jenner P
    Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.
    Smith LA; Tel BC; Jackson MJ; Hansard MJ; Braceras R; Bonhomme C; Chezaubernard C; Del Signore S; Rose S; Jenner P
    Mov Disord; 2002 Sep; 17(5):887-901. PubMed ID: 12360537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK; Banerji T; Jenner P; Marsden CD
    Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets.
    Tayarani-Binazir K; Jackson MJ; Rose S; McCreary AC; Jenner P
    Exp Neurol; 2010 Dec; 226(2):320-7. PubMed ID: 20843474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.
    Rose S; Jackson MJ; Smith LA; Stockwell K; Johnson L; Carminati P; Jenner P
    Eur J Pharmacol; 2006 Sep; 546(1-3):82-7. PubMed ID: 16925991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus).
    Maratos EC; Jackson MJ; Pearce RK; Jenner P
    Mov Disord; 2001 Jul; 16(4):631-41. PubMed ID: 11481686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
    Tayarani-Binazir KA; Jackson MJ; Fisher R; Zoubiane G; Rose S; Jenner P
    Eur J Pharmacol; 2010 Jun; 635(1-3):109-16. PubMed ID: 20303948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
    Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets.
    Jackson MJ; Smith LA; Al-Barghouthy G; Rose S; Jenner P
    Exp Neurol; 2007 Mar; 204(1):162-70. PubMed ID: 17113078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
    Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
    Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction.
    Stockwell KA; Scheller D; Rose S; Jackson MJ; Tayarani-Binazir K; Iravani MM; Smith LA; Olanow CW; Jenner P
    Exp Neurol; 2009 Oct; 219(2):533-42. PubMed ID: 19619533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque.
    Huot P; Johnston TH; Snoeren T; Koprich JB; Hill MP; Fox SH; Brotchie JM
    Eur J Neurosci; 2013 Mar; 37(5):831-8. PubMed ID: 23281915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets.
    Pearce RK; Jackson M; Britton DR; Shiosaki K; Jenner P; Marsden CD
    Psychopharmacology (Berl); 1999 Feb; 142(1):51-60. PubMed ID: 10102782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dopamine D(2) receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with L-dopa.
    Jackson MJ; Andree TH; Hansard M; Hoffman DC; Hurtt MR; Kehne JH; Pitler TA; Smith LA; Stack G; Jenner P
    J Neural Transm (Vienna); 2010 Jan; 117(1):55-67. PubMed ID: 19809864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
    Pearce RK; Jackson M; Smith L; Jenner P; Marsden CD
    Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets.
    Iravani MM; Costa S; Jackson MJ; Tel BC; Cannizzaro C; Pearce RK; Jenner P
    Eur J Neurosci; 2001 Feb; 13(3):597-608. PubMed ID: 11168568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.